BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 22290440)

  • 1. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.
    Biderman L; Poyurovsky MV; Assia Y; Manley JL; Prives C
    Mol Cell Biol; 2012 Apr; 32(7):1214-25. PubMed ID: 22290440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.
    Jacob AG; Singh RK; Comiskey DF; Rouhier MF; Mohammad F; Bebee TW; Chandler DS
    PLoS One; 2014; 9(8):e104444. PubMed ID: 25105592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
    Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
    Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 1 inhibits p53 signaling by dephosphorylating and stabilizing Mdmx.
    Lu Z; Wan G; Guo H; Zhang X; Lu X
    Cell Signal; 2013 Apr; 25(4):796-804. PubMed ID: 23277204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of p53: a collaboration between Mdm2 and Mdmx.
    Pei D; Zhang Y; Zheng J
    Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
    Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
    J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdmx promotes genomic instability independent of p53 and Mdm2.
    Carrillo AM; Bouska A; Arrate MP; Eischen CM
    Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles and regulation of MDM2 and MDMX: it is not just about p53.
    Klein AM; de Queiroz RM; Venkatesh D; Prives C
    Genes Dev; 2021 May; 35(9-10):575-601. PubMed ID: 33888565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
    Cai X; Yuan ZM
    J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.
    Okamoto K; Kashima K; Pereg Y; Ishida M; Yamazaki S; Nota A; Teunisse A; Migliorini D; Kitabayashi I; Marine JC; Prives C; Shiloh Y; Jochemsen AG; Taya Y
    Mol Cell Biol; 2005 Nov; 25(21):9608-20. PubMed ID: 16227609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.
    Egorova O; Lau HH; McGraphery K; Sheng Y
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
    Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
    EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
    Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MDMX acidic domain competes with the p53 transactivation domain for MDM2 N-terminal domain binding.
    Song Q; Liu XQ; Rainey JK
    Biochim Biophys Acta Mol Cell Res; 2022 Oct; 1869(10):119319. PubMed ID: 35780910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
    Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
    Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MdmX protects p53 from Mdm2-mediated degradation.
    Jackson MW; Berberich SJ
    Mol Cell Biol; 2000 Feb; 20(3):1001-7. PubMed ID: 10629057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.